Date: 2011-06-13
Type of information: Results
phase: 3
Announcement: results
Company: AB Science(France)
Product: masitinib
Action
mechanism: Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells.
Disease: canine atopic dermatitis
Therapeutic area: Veterinary diseases
Country:
Trial details:
Latest
news: AB Science SA has announced the publication of results from its phase 3 clinical trial investigating the treatment of canine atopic dermatitis with masitinib in Veterinary Dermatology, the lead journal in this field of research. The article entitled, ‘Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial’, shows that masitinib has potential as an effective treatment of canine atopic dermatitis. Important facts about this study include: Pivotal phase 3 study with one of the largest atopic dermatitis cohorts tested to date, 306 dogs ; Masitinib achieved statistically significant reduction in the signs of canine atopic dermatitis. Positive response to masitinib was evident for dogs resistant or intolerant to ciclosporin and/or corticosteroids, and dogs with severe pruritus; two populations with high unmet medical need. It could provide an important new tool in the veterinarian’s armamentarium for effective treatment of canine atopic dermatitis.
